GlassScriptPhysician profile
Sohail Cheema
NPI 1457483042
$541.35
in general payments reported to CMS, 2019-2025
12 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2021: $46.91 · 2022: $16.95 · 2023: $52.64 · 2024: $55.25 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $100.95 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $76.81 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $66.67 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Neos Therapeutics, LP | $43.12 | 2025 | Exxua |
| Lundbeck LLC | $42.18 | 2019 | |
| Allergan, INC. | $40.20 | 2019 | |
| Shire North American Group INC | $32.68 | 2019 | |
| Neurocrine Biosciences, INC. | $30.83 | 2024 | Ingrezza |
| Mallinckrodt Hospital Products INC. | $24.42 | 2024 | Terlivaz |
| Ironshore Pharmaceuticals INC. | $19.63 | 2019 | |
| Supernus Pharmaceuticals, INC. | $16.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Cheema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.